A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 432 participants.
Also called NCT02504294
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose other
- Phase
- Phase 3
- Enrolled
- 432 participants
- Registry
-
NCT02504294
-
- Other papers using this trial's data
- Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT02504294. Randomized; no masking; primary purpose other. Start 2015-07-13 (actual); primary completion 2016-07-02 (actual). Results posted on 2018-06-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
- Intervention (Biological)
- Epoetin Hospira Arm
- Intervention (Other)
- Standard of Care Arm
- Intervention (Drug)
- IV Iron
- Lead sponsor
- Pfizer
- Collaborator
- Hospira, now a wholly owned subsidiary of Pfizer
Record details
- Record id
cardio:ct-nct02504294- Content hash
dd64f1b13e31494742946221491bde88693627f278943456dceec7e86307d46f